|
Colorectal Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Colorectal cancers express the EphrinB ligand and its Eph receptors at significantly higher levels than numerous other cancer types, supporting Eph signaling inhibition as a potential new strategy for the broad treatment of colorectal carcinoma.
|
31545551 |
2019 |
|
Tumor Progression
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
EPH-A2, or ECK (a receptor for ephrin-A1), is ectopically expressed in most melanoma cell lines; the pathology where this expression is first manifested and the possible role of the receptor in tumor progression are unknown.
|
10502726 |
1999 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
EphA1 seems to be a marker of the differentiated normal epidermis and its downregulation in nonmelanoma skin cancer may contribute to carcinogenesis of these very frequent human tumors.
|
16862074 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EphA1 seems to be a marker of the differentiated normal epidermis and its downregulation in nonmelanoma skin cancer may contribute to carcinogenesis of these very frequent human tumors.
|
16862074 |
2006 |
|
Skin carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
EphA1 represents a new potential prognostic marker and therapeutic target in nonmelanoma skin cancer.
|
16862074 |
2006 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptors and their ephrin ligands are involved in normal hematopoietic development and tumorigenesis.
|
20061560 |
2010 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumour growth, invasiveness, angiogenesis and metastasis in vivo.
|
20179713 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumour growth, invasiveness, angiogenesis and metastasis in vivo.
|
20179713 |
2010 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumour growth, invasiveness, angiogenesis and metastasis in vivo.
|
20179713 |
2010 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
EphA1 protein expression was associated with depth of wall invasion (P=0.069), stage (P<0.001), and lymph node metastasis (P=0.018).
|
21042754 |
2010 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
EphA1 protein expression was associated with depth of wall invasion (P=0.069), stage (P<0.001), and lymph node metastasis (P=0.018).
|
21042754 |
2010 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptors, the largest subfamily of transmembrane tyrosine kinase receptors, have been increasingly implicated in various physiologic and pathologic processes, and the roles of the Eph family members during tumorigenesis have recently attracted growing attention.
|
21266352 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptors play important roles in the development of cancer.
|
23030051 |
2013 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptors play important roles in the development of cancer.
|
23030051 |
2013 |
|
melanoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Eph receptor tyrosine kinases and their ephrin ligands are considered to play important roles in melanoma progression and metastasis.
|
23358429 |
2013 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptor tyrosine kinases and their ephrin ligands are considered to play important roles in melanoma progression and metastasis.
|
23358429 |
2013 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
EphA1 and ephrin-A1 co-localized in pulmonary endothelial cells, and regulated vascular permeability and metastasis in the lungs.
|
23686306 |
2014 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
EphA1 is the first member of Eph superfamily and is involved in carcinogenesis.
|
24040450 |
2013 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Eph receptors have been documented in breast cancer, but the Ephrin ligands have not been thoroughly investigated.
|
24240587 |
2013 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Eph receptors have been documented in breast cancer, but the Ephrin ligands have not been thoroughly investigated.
|
24240587 |
2013 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Eph receptors as therapeutic targets in glioblastoma.
|
25144626 |
2014 |
|
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Eph receptors as therapeutic targets in glioblastoma.
|
25144626 |
2014 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptors and ephrin ligands are master regulators of oncogenic signaling required for proliferation, migration, and metastasis.
|
25258252 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptor/ephrin upregulation in cancer cells, the angiogenic vasculature, and injured or diseased tissues also offer opportunities for Eph/ephrin-based targeted drug delivery and imaging.
|
25292427 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptor/ephrin upregulation in cancer cells, the angiogenic vasculature, and injured or diseased tissues also offer opportunities for Eph/ephrin-based targeted drug delivery and imaging.
|
25292427 |
2015 |